Docetaxel and exisulind in hormone-refractory prostate cancer

Christopher Ryan, Walter M. Stadler, Nicholas J. Vogelzang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Single-agent docetaxel has been shown to produce a significant decrease in prostate-specific antigen (PSA) levels among patients with hormone-refractory prostate cancer (HRPC). A recent study also showed that exisulind, a sulfone metabolite of the nonsteroidal anti-inflammatory drug sulindac, lengthens the median PSA doubling time in men who had increasing PSA levels after radical prostatectomy. Furthermore, exisulind has shown significant antineoplastic activity in prostate cancer cell lines in vitro and in nude mouse xenograft models. Because preclinical studies have suggested synergistic interactions between docetaxel and exisulind, a phase I/II clinical trial combining these agents has been initiated in patients with HRPC. The primary objective of this study is to determine PSA response and measurable disease response rate of the combination therapy; secondary objectives include toxicity assessment and determination of time to disease progression, duration of response, and overall survival. Accrual is ongoing.

Original languageEnglish (US)
Pages (from-to)56-61
Number of pages6
JournalSeminars in Oncology
Volume28
Issue number4 SUPPL. 15
StatePublished - 2001
Externally publishedYes

Fingerprint

docetaxel
Prostate-Specific Antigen
Prostatic Neoplasms
Hormones
Sulindac
Phase II Clinical Trials
Clinical Trials, Phase I
Sulfones
Prostatectomy
Heterografts
Nude Mice
Antineoplastic Agents
Disease Progression
Anti-Inflammatory Agents
Cell Line
Survival
sulindac sulfone
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Ryan, C., Stadler, W. M., & Vogelzang, N. J. (2001). Docetaxel and exisulind in hormone-refractory prostate cancer. Seminars in Oncology, 28(4 SUPPL. 15), 56-61.

Docetaxel and exisulind in hormone-refractory prostate cancer. / Ryan, Christopher; Stadler, Walter M.; Vogelzang, Nicholas J.

In: Seminars in Oncology, Vol. 28, No. 4 SUPPL. 15, 2001, p. 56-61.

Research output: Contribution to journalArticle

Ryan, C, Stadler, WM & Vogelzang, NJ 2001, 'Docetaxel and exisulind in hormone-refractory prostate cancer', Seminars in Oncology, vol. 28, no. 4 SUPPL. 15, pp. 56-61.
Ryan C, Stadler WM, Vogelzang NJ. Docetaxel and exisulind in hormone-refractory prostate cancer. Seminars in Oncology. 2001;28(4 SUPPL. 15):56-61.
Ryan, Christopher ; Stadler, Walter M. ; Vogelzang, Nicholas J. / Docetaxel and exisulind in hormone-refractory prostate cancer. In: Seminars in Oncology. 2001 ; Vol. 28, No. 4 SUPPL. 15. pp. 56-61.
@article{62c4b9f4a2394d9ab0f439862f1b3e4b,
title = "Docetaxel and exisulind in hormone-refractory prostate cancer",
abstract = "Single-agent docetaxel has been shown to produce a significant decrease in prostate-specific antigen (PSA) levels among patients with hormone-refractory prostate cancer (HRPC). A recent study also showed that exisulind, a sulfone metabolite of the nonsteroidal anti-inflammatory drug sulindac, lengthens the median PSA doubling time in men who had increasing PSA levels after radical prostatectomy. Furthermore, exisulind has shown significant antineoplastic activity in prostate cancer cell lines in vitro and in nude mouse xenograft models. Because preclinical studies have suggested synergistic interactions between docetaxel and exisulind, a phase I/II clinical trial combining these agents has been initiated in patients with HRPC. The primary objective of this study is to determine PSA response and measurable disease response rate of the combination therapy; secondary objectives include toxicity assessment and determination of time to disease progression, duration of response, and overall survival. Accrual is ongoing.",
author = "Christopher Ryan and Stadler, {Walter M.} and Vogelzang, {Nicholas J.}",
year = "2001",
language = "English (US)",
volume = "28",
pages = "56--61",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 15",

}

TY - JOUR

T1 - Docetaxel and exisulind in hormone-refractory prostate cancer

AU - Ryan, Christopher

AU - Stadler, Walter M.

AU - Vogelzang, Nicholas J.

PY - 2001

Y1 - 2001

N2 - Single-agent docetaxel has been shown to produce a significant decrease in prostate-specific antigen (PSA) levels among patients with hormone-refractory prostate cancer (HRPC). A recent study also showed that exisulind, a sulfone metabolite of the nonsteroidal anti-inflammatory drug sulindac, lengthens the median PSA doubling time in men who had increasing PSA levels after radical prostatectomy. Furthermore, exisulind has shown significant antineoplastic activity in prostate cancer cell lines in vitro and in nude mouse xenograft models. Because preclinical studies have suggested synergistic interactions between docetaxel and exisulind, a phase I/II clinical trial combining these agents has been initiated in patients with HRPC. The primary objective of this study is to determine PSA response and measurable disease response rate of the combination therapy; secondary objectives include toxicity assessment and determination of time to disease progression, duration of response, and overall survival. Accrual is ongoing.

AB - Single-agent docetaxel has been shown to produce a significant decrease in prostate-specific antigen (PSA) levels among patients with hormone-refractory prostate cancer (HRPC). A recent study also showed that exisulind, a sulfone metabolite of the nonsteroidal anti-inflammatory drug sulindac, lengthens the median PSA doubling time in men who had increasing PSA levels after radical prostatectomy. Furthermore, exisulind has shown significant antineoplastic activity in prostate cancer cell lines in vitro and in nude mouse xenograft models. Because preclinical studies have suggested synergistic interactions between docetaxel and exisulind, a phase I/II clinical trial combining these agents has been initiated in patients with HRPC. The primary objective of this study is to determine PSA response and measurable disease response rate of the combination therapy; secondary objectives include toxicity assessment and determination of time to disease progression, duration of response, and overall survival. Accrual is ongoing.

UR - http://www.scopus.com/inward/record.url?scp=0034794830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034794830&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 56

EP - 61

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL. 15

ER -